Cooperative Agreement U01AI195203
Award Date 8/5/26
Completion Date 6/30/30
Dollars Obligated $525K
Federal Agency
Federal Grant Program
Assistance Type
Cooperative Agreement
Place of Performance
Great Britain, United Kingdom
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. $223,728 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate Plasmodium falciparum gametocyte differentiation and adhesion mechanisms as part of Project Grant R21AI199783. The funded research addresses malaria transmission by examining the sexual stage parasites (gametocytes) responsible for...
- The National Institute of Allergy and Infectious Diseases awarded Tufts Medical Center Parent, Inc. (doing business as Tufts Medical Center) $506,415 on February 9, 2026, for research on pre- and post-exposure prophylaxis of tick-transmitted babesiosis using the antimalarial drug tafenoquine under the Allergy and Infectious Diseases Research program (CFDA 93.855). The research evaluates tafenoquine's potential to prevent Babesia microti infection transmitted by Ixodes scapularis nymphs. The...
- The National Institute of Allergy and Infectious Diseases awarded the University of Washington $824,264 on June 8, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to advance clinical readiness of PBVIVAC, a novel transgenic live attenuated sporozoite vaccine for Plasmodium vivax malaria. PBVIVAC combines P. berghei parasites engineered to express P. vivax circumsporozoite antigen, leveraging P. berghei's ease of laboratory propagation and natural attenuation in...
- The National Institute of Allergy and Infectious Diseases awarded Brown University $791,611 on April 10, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to discover and develop novel antimalarial drugs targeting PFGARP as a parenteral therapy for severe falciparum malaria. The project conducts a targeted high-throughput drug screen to identify compounds that mimic the lethal activity of antibodies recognizing PFGARP, optimizes and down-selects lead candidates,...
- The National Institute of Allergy and Infectious Diseases, a component of the Department of Health and Human Services National Institutes of Health, awarded Purdue University $239,023 on August 21, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop covalent phosphatidylinositol 4-kinase (PI4K) inhibitors targeting malaria parasites. The project executes hit-to-lead optimization of high-priority molecular scaffolds against Plasmodium species that inhibit...
- The National Institute of Allergy and Infectious Diseases awarded Case Western Reserve University $631,401 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop human monoclonal antibodies targeting Plasmodium vivax malaria. The research focuses on isolating and optimizing monoclonal antibodies (MAbs) that target the parasite's apical membrane protein 1 (AMA1) and circumsporozoite protein (CSP) to prevent and treat vivax malaria, which...
- The National Institute of Allergy and Infectious Diseases awarded The Regents of the University of California, San Francisco $810,125 on June 9, 2026, to evaluate how perennial malaria chemoprevention (PMC) in early childhood affects the development of naturally acquired immunity to Plasmodium falciparum malaria. The award is made under the Allergy and Infectious Diseases Research program (CFDA 93.855). The recipient will conduct a comprehensive analysis of samples already collected from a...
- The National Institute of Allergy and Infectious Diseases awarded the National Science And Technology Development Agency $117,504 on September 24, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The recipient will conduct biochemical investigations of two Plasmodium falciparum folate transporters, PFFT1 and PFFT2, to characterize their function and substrate scope. The work will assess the transporters' ability to transport antifolate drugs, identify...
- The National Institute of Allergy and Infectious Diseases, part of the Department of Health and Human Services, awarded The Leland Stanford Junior University $1,818,562 on May 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to evaluate optimal antimalarial chemoprevention regimens combined with the R21 malaria vaccine in perennial, high-transmission settings. The research will test whether combining the R21 vaccine with either monthly...
- The National Institute of Allergy and Infectious Diseases awarded the Research Institute at Nationwide Children's Hospital $179,010 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to characterize multiple organ dysfunction syndrome in children with severe malaria and identify distinct disease phenotypes and their underlying mechanisms. The recipient will identify and phenotype multiple organ dysfunction in children presenting with cerebral malaria...